Page 6 - Click Chemistry News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs
VERAXA Biotech and Quadira Biosciences Enter Partnership on ADC Development
HEIDELBERG, Germany and ZUG, Switzerland, June 14, 2021 / B3C newswire / VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), a leading company in innovative ADC engineering and functional antibody screening, announced today that it has entered into a partnership agreement with Quadira Biosciences AG, Zug, Switzerland, to jointly develop a suite of novel ADCs for the treatment of oncological conditions. The collaboration will leverage both the advantages of VERAXA s advanced and proprietary position-true click-chemistry-based drug conjugation technology in combination with Quadira’s superior 3D cellular assay and assessment systems. The agreement provides that VERAXA will be entitled to upfront payments and royalties from the worldwide sale of products resulting from the collaboration. Further details of the agreement were not disclosed. ....

Baden Wüberg , Araxa Biosciences Gmb , Christoph Antz , Quadira Biosciences , Arne Faiss , Xlife Sciences , European Molecular Biology Laboratory , Velabs Therapeutics Gmbh , Joint Venture , Araxa Biosciences Gmbh , Precision Medicine , Drug Evaluation , Medical Oncology , Click Chemistry , High Throughput Screening Assays , Drug Screening Assays , Pharmaceutical Preparations , அராக்ஸா உயிர் அறிவியல் க்ம்ப் , கிறிஸ்டோஃப் அன்டஸ் , ஐரோப்பிய மூலக்கூறு உயிரியல் ஆய்வகம் , கூட்டு துணிகர , அராக்ஸா உயிர் அறிவியல் கஂப் , ப்ரிஸிஶந் மருந்து , மருந்து மதிப்பீடு , மருத்துவ புற்றுநோயியல் , கிளிக் செய்க வேதியியல் ,